AI-Derived Software in Chest X-Ray Analysis: A NICE Perspective

By Staff Writer

October 10, 2023

A recent update has been published by NICE (National Institute for Health and Care Excellence). It described the use of artificial intelligence (AI)-derived software in analysing chest X-rays for suspected lung cancer. This has been under scrutiny in primary care referrals. This initiative is part of the NHS’s ambition to diagnose 75% of all cancers at stages 1 or 2 by 2028.

Potential Benefits of AI-Derived Software in Chest X-Ray Analysis

The AI-equipped software can detect lung abnormalities in chest X-ray images automatically. It can assist radiologists and reporting radiographers in interpreting these images. This aids in making clinical decisions about the need for further investigations or CT scans. The software can distinguish between normal and abnormal images. It can also highlight suspected abnormalities. It allows for prioritizing the review of chest X-rays. This could potentially accelerate the referral process to CT scans. 


However, the committee noted that trust in AI-derived software for patients and healthcare professionals was crucial for its efficient use. This would require standardisation of technologies and further research in the setting of interest. Prospective studies need to be conducted in a population referred from primary care to reflect how the NHS would use the software in clinical practice. 


The committee also highlighted that AI-derived software could be particularly beneficial for certain groups. It could improve lung cancer detection in people with underlying lung conditions. These include asthma, chronic obstructive pulmonary disease (COPD), people with a family background of lung cancer, and younger women who do not smoke.

Potential Risks and Challenges in the Use of AI-Derived Software

However, the committee also pointed out potential risks associated with using AI-derived software. These include the cost of the AI-derived software. This may not be offset by cost and resource savings later in the pathway. Lower specificity to detect cancerous nodules and other abnormalities that suggest cancer could result in more people without cancer having CT scans. This could have cost and disutility implications.

In conclusion, while AI-derived software shows promise in aiding the early detection of lung cancer, more research and standardisation are needed to ensure its efficient and effective use in clinical practice. You should also carefully consider the potential benefits and risks associated with its use.

Reference url

Recent Posts

DTC telehealth partnerships
           

DTC Telehealth Partnerships: Navigating Risks in Pharma’s Digital Expansion

🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?

Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.

Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.

#SyenzaNews #DigitalHealth #HealthEconomics #HealthcarePolicy

MAF Test breast cancer
       

MAF Test Breast Cancer: Revolutionizing Personalized Treatment in Spanish Oncology

🌟 How can personalized medicine transform breast cancer treatment in Spain?

The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.

Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.

#SyenzaNews #precisionmedicine #HealthEconomics #innovation

ribociclib breast cancer guidance
           

NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patients in the NHS

🌟 Are we on the brink of transforming breast cancer treatment?

NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.

Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.

#SyenzaNews #oncology #costeffectiveness #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.